AAM Opposes Oregon’s SB 764 Settlements Bill
Association Says ‘Unnecessary’ Legislation Will Delay Access And Drive Up Prices
Executive Summary
Proposed state legislation restricting patent settlements set out in Oregon’s SB 764 bill is “unnecessary,” the AAM has insisted, opposing the “unconstitutional” legislation by citing delayed patient access to affordable medicines, the obstruction of expedited patent settlements and benefits to brand-name pharmaceutical companies which will eventually lead to price rises.